ANXA1 and lung cancer: Furthermore, the overexpression of ANXA1 decreased chemosensitivity to Osimertinib in lung cancer cells and the knockdown of ANXA1 increased chemosensitivity to Osimertinib in lung cancer cells with the Osimertinib-resistant C797S mutation.